CORRECTIONS

Author Corrections

The October 20, 2012, review article by Higano, entitled “Sexuality and Intimacy After Definitive Treatment and Subsequent Androgen Deprivation Therapy for Prostate Cancer” (J Clin Oncol 30:3720-3725, 2012), contained an error.

In the References section, reference number 34 was given as:

34. Wibowo E, Deurveilher S, Wassersug RJ, et al: Estradiol treatment modulates spontaneous sleep and recovery after sleep deprivation in castrated male rats. Behav Brain Res 226:456-464, 2012

Whereas it should have been:

34. Wibowo E, Schellhammer P, Wassersug RJ: Role of estrogen in normal male function: Clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol 185:17-23, 2011

The author apologizes for the mistake.

DOI: 10.1200/JCO.2013.48.9492; published February 20, 2013

The November 10, 2012, Biology of Neoplasia article by Bottsford-Miller, Coleman, and Sood, entitled “Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies” (J Clin Oncol 30:4026-4034, 2012), contained an error.

In the section “Targeting VEGF,” bevacizumab was defined in the third sentence as “monoclonal antibody against

VEGF-A165,” whereas it should have been defined as “monoclonal antibody against VEGF,” as follows:

“Bevacizumab (monoclonal antibody against VEGF) was among the initial antiangiogenic agents developed.¹⁰”

The authors apologize for the mistake.

DOI: 10.1200/JCO.2013.48.9500; published February 20, 2013

The January 1, 2013, article by Kovalchik et al, entitled “Absolute Risk Prediction of Second Primary Thyroid Cancer Among 5-Year Survivors of Childhood Cancer” (J Clin Oncol 31:119-127, 2013), contained an error.

In Table 2, under M3, the relative risk for the radiation dose (exponential term) was given as -0.60 , whereas it should have been -0.06 .

The authors apologize for the mistake.

DOI: 10.1200/JCO.2013.48.9518; published February 20, 2013